Exploring Association of FGFR3 Alterations in Urothelial Cancer With Arlene Siefker-Radtke, MD

At this year’s American Society of Clinical Oncology (ASCO) Annual Meeting, Oncology Data Advisor sat down with Dr. Arlene Siefker-Radtke, Professor in the Department of Genitourinary Medical Oncology at MD Anderson Cancer Center, to discuss her presentation entitled “FGFR3 alterations in patients who develop locally advanced or metastatic urothelial cancer and their association with tumor subtype and clinical outcomes in patients treated with erdafitinib vs pembrolizumab.”

Listen in to hear more about:

• The incidence of FGFR3 alterations in urothelial cancer and their implications for treatment
• Her team’s molecular analysis of the phase 3 THOR study, which compared erdafitinib versus pembrolizumab for patients with metastatic urothelial cancer
• The incidence of luminal-papillary subtype tumors harboring FGFR3 alterations found in their molecular classification of tumors in the study
• Implications for clinical outcomes and treatment responses
• Next steps and more!

About Dr. Siefker-Radtke

Arlene Siefker-Radtke, MD, is a Professor in the Department of Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center, where she has specialized in the treatment of urothelial cancer for more than 20 years. Her research focuses on developing novel therapies for urothelial cancer and other rare tumors of the bladder and upper urinary tract, including immunotherapy, fibroblast growth factor receptor inhibitors, and neoadjuvant chemotherapy. Dr. Siefker-Radtke is actively in the National Comprehensive Cancer Network (NCCN) Oncology Research Program, the NCCN Bladder/Penile Cancers Panel, and the National Institutes of Health (NIH) Bladder Cancer Task Force.